128 related articles for article (PubMed ID: 37919070)
21. Systems biology strategy and experimental validation to uncover the pharmacological mechanism of Xihuang Pill in treating non-small cell lung cancer.
Zhuang Z; Huang D; Sheng ZR; Ye ZJ; Jiang H; Yuan Y; Qin B; Zhao Y; Pan HF; Tang Y
Phytomedicine; 2023 Jan; 108():154491. PubMed ID: 36368285
[TBL] [Abstract][Full Text] [Related]
22. Analysis of the Significance of Immune Cell Infiltration and Prognosis of Non-Small-Cell Lung Cancer by Bioinformatics.
Sun H; Sui B; Li Y; Yan J; Cao M; Zhang L; Liu S
J Healthc Eng; 2021; 2021():3284186. PubMed ID: 34603645
[TBL] [Abstract][Full Text] [Related]
23. Identification of tumor immune infiltration-associated lncRNAs for improving prognosis and immunotherapy response of patients with non-small cell lung cancer.
Sun J; Zhang Z; Bao S; Yan C; Hou P; Wu N; Su J; Xu L; Zhou M
J Immunother Cancer; 2020 Feb; 8(1):. PubMed ID: 32041817
[TBL] [Abstract][Full Text] [Related]
24. Development of a copper metabolism-related gene signature in lung adenocarcinoma.
Chang W; Li H; Zhong L; Zhu T; Chang Z; Ou W; Wang S
Front Immunol; 2022; 13():1040668. PubMed ID: 36524120
[TBL] [Abstract][Full Text] [Related]
25. Integrative Analysis of m6A RNA Methylation Regulators and the Tumor Immune Microenvironment in Non-Small-Cell Lung Cancer.
Zhu J; Jiang Y; Wang T; Wu A; Zhou T; Zhang A; Tang Y; Shen Z; Wang J; Zhou H; Shi J; Chen J
Dis Markers; 2022; 2022():2989200. PubMed ID: 35186164
[TBL] [Abstract][Full Text] [Related]
26. Exploration of Novel Immunological Terms in Lung Cancer With Large Populations: Implications for Immunotherapy.
Yao Y; Wang J; Yang F; Gao W
Front Immunol; 2022; 13():924498. PubMed ID: 35844536
[TBL] [Abstract][Full Text] [Related]
27. Immune checkpoints related-LncRNAs can identify different subtypes of lung cancer and predict immunotherapy and prognosis.
Zhang H; Liu M; Du G; Yu B; Ma X; Gui Y; Cao L; Li X; Tan B
J Cancer Res Clin Oncol; 2022 Jul; 148(7):1597-1612. PubMed ID: 35296921
[TBL] [Abstract][Full Text] [Related]
28. PD-L1 expression and T cells infiltration in patients with uncommon EGFR-mutant non-small cell lung cancer and the response to immunotherapy.
Chen K; Cheng G; Zhang F; Zhu G; Xu Y; Yu X; Huang Z; Fan Y
Lung Cancer; 2020 Apr; 142():98-105. PubMed ID: 32120230
[TBL] [Abstract][Full Text] [Related]
29. Spatial transcriptomics of macrophage infiltration in non-small cell lung cancer reveals determinants of sensitivity and resistance to anti-PD1/PD-L1 antibodies.
Larroquette M; Guegan JP; Besse B; Cousin S; Brunet M; Le Moulec S; Le Loarer F; Rey C; Soria JC; Barlesi F; Bessede A; Scoazec JY; Soubeyran I; Italiano A
J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35618288
[TBL] [Abstract][Full Text] [Related]
30. Triple blockade of Ido-1, PD-L1 and MEK as a potential therapeutic strategy in NSCLC.
Della Corte CM; Ciaramella V; Ramkumar K; Vicidomini G; Fiorelli A; Nardone V; Cappabianca S; Cozzolino I; Zito Marino F; Di Guida G; Wang Q; Cardnell R; Gay CM; Ciardiello D; Martinelli E; Troiani T; Martini G; Napolitano S; Wang J; Byers LA; Ciardiello F; Morgillo F
J Transl Med; 2022 Nov; 20(1):541. PubMed ID: 36419183
[TBL] [Abstract][Full Text] [Related]
31. Knock-down of PSAT1 Enhances Sensitivity of NSCLC Cells to Glutamine-limiting Conditions.
Jin HO; Hong SE; Kim JY; Jang SK; Kim YS; Sim JH; Oh AC; Kim H; Hong YJ; Lee JK; Park IC
Anticancer Res; 2019 Dec; 39(12):6723-6730. PubMed ID: 31810937
[TBL] [Abstract][Full Text] [Related]
32. High expression of MYEOV reflects poor prognosis in non-small cell lung cancer.
Zhang R; Ma A
Gene; 2021 Feb; 770():145337. PubMed ID: 33278551
[TBL] [Abstract][Full Text] [Related]
33. Prediction of lung squamous cell carcinoma immune microenvironment and immunotherapy efficiency with pyroptosis-derived genes.
Deng X; Wang Z; Luo Y; Li Z; Chen L
Medicine (Baltimore); 2022 Sep; 101(37):e30304. PubMed ID: 36123889
[TBL] [Abstract][Full Text] [Related]
34.
Lin Y; Wang Y; Xue Q; Zheng Q; Chen L; Jin Y; Huang Z; Li Y
Transl Lung Cancer Res; 2024 May; 13(5):1010-1031. PubMed ID: 38854942
[TBL] [Abstract][Full Text] [Related]
35. Integration of comprehensive genomic profiling, tumor mutational burden, and PD-L1 expression to identify novel biomarkers of immunotherapy in non-small cell lung cancer.
Shi Y; Lei Y; Liu L; Zhang S; Wang W; Zhao J; Zhao S; Dong X; Yao M; Wang K; Zhou Q
Cancer Med; 2021 Apr; 10(7):2216-2231. PubMed ID: 33655698
[TBL] [Abstract][Full Text] [Related]
36. A cellular senescence-related classifier based on a tumorigenesis- and immune infiltration-guided strategy can predict prognosis, immunotherapy response, and candidate drugs in hepatocellular carcinoma.
Luo Y; Liu H; Fu H; Ding GS; Teng F
Front Immunol; 2022; 13():974377. PubMed ID: 36458010
[TBL] [Abstract][Full Text] [Related]
37. [CD45RO⁺ Memory T Lymphocytes As A Candidate Marker for Non-small Cell Lung Cancer].
Tan Q; Li H; Yu M; Tang X; Tan J; Zhang S; Wang J
Zhongguo Fei Ai Za Zhi; 2021 Apr; 24(4):254-264. PubMed ID: 33910273
[TBL] [Abstract][Full Text] [Related]
38. Machine learning reveals a PD-L1-independent prediction of response to immunotherapy of non-small cell lung cancer by gene expression context.
Wiesweg M; Mairinger F; Reis H; Goetz M; Kollmeier J; Misch D; Stephan-Falkenau S; Mairinger T; Walter RFH; Hager T; Metzenmacher M; Eberhardt WEE; Zaun G; Köster J; Stuschke M; Aigner C; Darwiche K; Schmid KW; Rahmann S; Schuler M
Eur J Cancer; 2020 Nov; 140():76-85. PubMed ID: 33059196
[TBL] [Abstract][Full Text] [Related]
39. [Immune Microenvironment Comparation Study between EGFR Mutant and EGFR Wild Type Lung Adenocarcinoma Patients Based on TCGA Database].
Zhu G; Li Y; Shi R; Xu S; Zhang Z; Cao P; Chen C; Liu H; Chen J
Zhongguo Fei Ai Za Zhi; 2021 Apr; 24(4):236-244. PubMed ID: 33910272
[TBL] [Abstract][Full Text] [Related]
40. The Impact of NOTCH Pathway Alteration on Tumor Microenvironment and Clinical Survival of Immune Checkpoint Inhibitors in NSCLC.
Li X; Wang Y; Li X; Feng G; Hu S; Bai Y
Front Immunol; 2021; 12():638763. PubMed ID: 34305884
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
